[go: up one dir, main page]

TR200001981T2 - Farmasötik açıdan salınımı uzatılmış oral dozaj şekli - Google Patents

Farmasötik açıdan salınımı uzatılmış oral dozaj şekli

Info

Publication number
TR200001981T2
TR200001981T2 TR2000/01981T TR200001981T TR200001981T2 TR 200001981 T2 TR200001981 T2 TR 200001981T2 TR 2000/01981 T TR2000/01981 T TR 2000/01981T TR 200001981 T TR200001981 T TR 200001981T TR 200001981 T2 TR200001981 T2 TR 200001981T2
Authority
TR
Turkey
Prior art keywords
dosage form
extended
pharmaceutically
oral dosage
atpase inhibitor
Prior art date
Application number
TR2000/01981T
Other languages
English (en)
Inventor
Karehill Per-Gunnar
Johan Lundberg Per
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200001981T2 publication Critical patent/TR200001981T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

H+ , K+ -ATPaz inhibitörünün uzatilmis bir plazma konsantrasyonu profilini veren bir H+ , K+ -ATPaz inhibitörünün farmasötik açidan salinimi uzatilmis olan enterik kapli dozaj sekli. Uzatilmis plazma profili, hidrofilik ya da hidrofobik bir matriks çekirdek maddesini ve H+ , K+ -ATPaz inhibitörünün ve istege bagli olarak farmasötik açidan kabul edilebilir yardimci maddeleri kapsayan farmasötik bir bilesim yolu ile elde edilir. Dozaj sekli, günde bir kez tatbik edilebilir.
TR2000/01981T 1997-12-22 1998-12-17 Farmasötik açıdan salınımı uzatılmış oral dozaj şekli TR200001981T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
TR200001981T2 true TR200001981T2 (tr) 2000-11-21

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01981T TR200001981T2 (tr) 1997-12-22 1998-12-17 Farmasötik açıdan salınımı uzatılmış oral dozaj şekli

Country Status (38)

Country Link
US (1) US6605303B1 (tr)
EP (1) EP1043976B1 (tr)
JP (1) JP4865945B2 (tr)
KR (2) KR20060097069A (tr)
CN (1) CN1171582C (tr)
AR (1) AR017201A1 (tr)
AT (1) ATE312602T1 (tr)
AU (1) AU759634B2 (tr)
BG (1) BG65028B1 (tr)
BR (1) BR9814378A (tr)
CA (1) CA2315261C (tr)
CY (1) CY1106072T1 (tr)
CZ (1) CZ299228B6 (tr)
DE (1) DE69832816T2 (tr)
DK (1) DK1043976T3 (tr)
DZ (1) DZ2685A1 (tr)
EE (1) EE04901B1 (tr)
ES (1) ES2252875T3 (tr)
HR (1) HRP20000380B1 (tr)
HU (1) HUP0101437A3 (tr)
IL (2) IL136827A0 (tr)
IS (1) IS5524A (tr)
MA (1) MA26576A1 (tr)
MY (1) MY126555A (tr)
NO (1) NO20003218L (tr)
NZ (1) NZ505127A (tr)
PL (1) PL193776B1 (tr)
RU (1) RU2214232C2 (tr)
SA (1) SA99191077B1 (tr)
SE (1) SE9704869D0 (tr)
SK (1) SK284988B6 (tr)
TN (1) TNSN98229A1 (tr)
TR (1) TR200001981T2 (tr)
TW (1) TWI249410B (tr)
UA (1) UA69397C2 (tr)
WO (1) WO1999032091A1 (tr)
YU (1) YU36700A (tr)
ZA (1) ZA9811239B (tr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1308159T3 (da) * 1995-09-21 2005-02-14 Pharma Pass Ii Llc Farmaceutisk sammensætning indeholdende en syre-labil omeprazol og fremgangsmåde til fremstilling deraf
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DK1037607T3 (da) 1997-12-08 2004-06-21 Altana Pharma Ag Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
EP1341528B1 (en) * 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
KR20050065550A (ko) * 2002-09-26 2005-06-29 아스텔라스세이야쿠 가부시키가이샤 약물 흡수성 개선제
EP2596791B1 (en) 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
JP5592902B2 (ja) 2009-03-09 2014-09-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療薬の徐放性組成物
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US9050263B2 (en) 2013-02-13 2015-06-09 Redhill Biopharma Ltd. Pharmaceutical compositions for the treatment of Helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (tr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
CA2193681A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
SI0723436T1 (en) * 1994-07-08 2002-02-28 Astrazeneca Ab Multiple unit tableted dosage form i
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
CN1284866A (zh) 2001-02-21
DK1043976T3 (da) 2006-03-20
ATE312602T1 (de) 2005-12-15
BG104620A (en) 2001-04-30
NO20003218L (no) 2000-08-22
AR017201A1 (es) 2001-08-22
HRP20000380A2 (en) 2001-06-30
PL193776B1 (pl) 2007-03-30
NZ505127A (en) 2003-02-28
JP4865945B2 (ja) 2012-02-01
US6605303B1 (en) 2003-08-12
CA2315261C (en) 2008-02-12
SK284988B6 (sk) 2006-04-06
DE69832816T2 (de) 2006-08-31
KR100755154B1 (ko) 2007-09-04
DZ2685A1 (fr) 2003-03-29
IL136827A0 (en) 2001-06-14
JP2001526211A (ja) 2001-12-18
HK1034455A1 (en) 2001-10-26
TWI249410B (en) 2006-02-21
ES2252875T3 (es) 2006-05-16
WO1999032091A1 (en) 1999-07-01
ZA9811239B (en) 1999-06-22
KR20060097069A (ko) 2006-09-13
BG65028B1 (bg) 2006-12-29
AU759634B2 (en) 2003-04-17
NO20003218D0 (no) 2000-06-21
BR9814378A (pt) 2000-10-10
SK8072000A3 (en) 2001-01-18
CN1171582C (zh) 2004-10-20
AU1991299A (en) 1999-07-12
SA99191077B1 (ar) 2006-07-11
EP1043976B1 (en) 2005-12-14
YU36700A (sh) 2003-01-31
SE9704869D0 (sv) 1997-12-22
EE200000383A (et) 2001-12-17
CA2315261A1 (en) 1999-07-01
IL136827A (en) 2007-05-15
CZ299228B6 (cs) 2008-05-21
EE04901B1 (et) 2007-10-15
DE69832816D1 (de) 2006-01-19
MA26576A1 (fr) 2004-12-20
HRP20000380B1 (en) 2007-08-31
CZ20002314A3 (cs) 2000-11-15
HUP0101437A2 (hu) 2001-10-28
IS5524A (is) 2000-06-08
TNSN98229A1 (fr) 2005-03-15
CY1106072T1 (el) 2011-06-08
PL341428A1 (en) 2001-04-09
KR20010033428A (ko) 2001-04-25
EP1043976A1 (en) 2000-10-18
RU2214232C2 (ru) 2003-10-20
UA69397C2 (uk) 2004-09-15
MY126555A (en) 2006-10-31
HUP0101437A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
TR200001981T2 (tr) Farmasötik açıdan salınımı uzatılmış oral dozaj şekli
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
TR199903053T2 (tr) Benzimidazol türevleri.
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
MX9402938A (es) Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible.
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
ECSP083351A (es) Composiciones farmacéuticas
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
TR199800902T2 (tr) Ecza formülasyonlari.
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
NO20016346D0 (no) Ny formulering
TR200200982T2 (tr) Farmasötik bileşim terkipleri.
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
CY1105795T1 (el) Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
DE69927374T2 (de) Entzündungshemmende pharmazeutische formulierungen
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
SE0102309D0 (sv) Farmaceutisk engång-om-dagen-komposition innehållande brivudin